Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome
Completed · Phase 2 · NCT02352896
Conditions: Leigh Syndrome
At a glance
- Research payments reported, 2025
- $21,515
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- PTC Therapeutics
- Tested
- EPI-743 (drug)
- Dates
- Started 2014-01-31; completion 2023-10-30
- Results posted
- Not yet
EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002 (NCT01721733) study.
From ClinicalTrials.gov, last updated 2024-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ptc Therapeutics, Inc. reported $21,515 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.